Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Shares Outstanding (2016 - 2025)

Historic Shares Outstanding for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $215.9 million.

  • Ocular Therapeutix's Shares Outstanding rose 3688.01% to $215.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $215.9 million, marking a year-over-year increase of 3688.01%. This contributed to the annual value of $215.9 million for FY2025, which is 3688.01% up from last year.
  • Latest data reveals that Ocular Therapeutix reported Shares Outstanding of $215.9 million as of Q4 2025, which was up 3688.01% from $174.9 million recorded in Q3 2025.
  • In the past 5 years, Ocular Therapeutix's Shares Outstanding registered a high of $215.9 million during Q4 2025, and its lowest value of $76.2 million during Q1 2021.
  • In the last 5 years, Ocular Therapeutix's Shares Outstanding had a median value of $79.3 million in 2023 and averaged $115.6 million.
  • In the last 5 years, Ocular Therapeutix's Shares Outstanding skyrocketed by 52.66% in 2022 and then skyrocketed by 9957.53% in 2024.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Shares Outstanding stood at $76.7 million in 2021, then rose by 0.61% to $77.2 million in 2022, then surged by 48.91% to $115.0 million in 2023, then surged by 37.22% to $157.7 million in 2024, then surged by 36.88% to $215.9 million in 2025.
  • Its Shares Outstanding was $215.9 million in Q4 2025, compared to $174.9 million in Q3 2025 and $172.9 million in Q2 2025.